| GlaxoSmithKline AG - Fluarix, Injektionssuspension | | 70042 | | 01 | | Fluarix | | Injektionssuspension | | J07BB02 | | Influenza, gereinigtes Antigen | | 04.09.2025 | | |
| | Zusammensetzung | | haemagglutininum influenzae A (H1N1) (Virus Stamm A/Victoria/4897/2022 (H1N1)pdm09-like: reassortant virus IVR-238 derived from A/Victoria/4897/2022) 15 µg, haemagglutininum influenzae A (H3N2) (Virus Stamm A/Thailand/8/2022 (H3N2)-like: reassortant virus IVR-237 derived from A/Thailand/8/2022) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Austria/1359417/2021-like: reassortant virus BVR-26 derived from B/Austria/1359417/2021 (Victoria lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.7 mg, kalium 0.1 mg, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. | | Packungsbestandteile | | | | Packungsnummer | Packungsgrösse | EFP | PP | Kat. | SL | In Refdata nicht gelistet |
|---|
| 001 | | | | B | | Ja | | 002 | 10 | | | B | | Ja |
|
|
